ひとくちメモ/山口英世先生
|
|
- あいね いさし
- 5 years ago
- Views:
Transcription
1 Epidemiology of antifungal resistance : current status and future perspective Hideyo YAMAGUCHI MCZ MCFG 7 4 MRSA Candida spp. MCZ a B b MCFG P45 4αCYP5 c DNA d CYP5 CYP5,3-D-,3-D-,3-D- a b c P45 P454DM datp-binding casette ABC CDR CDR CDR Teikyo University Institute of Medical Mycology (TIMM) (359 Otsuka, Hachioji, Tokyo)
2 5 6 drug resistance MIC antifungal resistance antibacterial resistance Aspergillus spp. MCFG Cryptococcus neoformans Candida albicans C. albicans 2 Aspergillus fumigatus 3 Candida spp. Aspergillus spp. 9, 4 Candida spp. C. glabrata, C. krusei, C. albicans 6 Candida spp. C. lusitaniae C. guilliermondii 8
3 C. krusei C. glabrata non-albicans Candida 5 MCFG Trichosporon spp. 6, 7 clinical resistance 6 MIC MIC 2 CLSI Clinical Laboratory Standards Institute 99 2 M27-A M27-A3 8 M38-A M38-A2 9 M44- A M44-A2 2 2 In vitro MIC in vivo MIC PK PD Candida spp.,, MCFG 22, 23 in vitro in vivo MIC MIC MIC Cr. neoformans
4 Candida spp. MIC CLSI M27 CLSI M27-S3 22 a MCFG S MIC µg ml S-DD I 8 6 a posaconazole caspofungin anidulafungin b S NSR R b NS 2 24, 25 Candida spp. MIC, µg ml 8 CLSI M38- A2 9 Aspergillus spp. 2µg ml,, 4µg ml A. fumigatus MIC 8µg ml 3, 26 in vitro in vivo 27, 28 CLSI Antifungal Susceptibility Testing Subcommittee of EUCAST ; EUCAST-AFST 29 MIC 3-2 8S 6S 4S 7S 5S 3S RNA 6, 3, 32 P45 4 α - 3 -D- DNA - RNA
5 7S 7 5-7,, 33-6, 3, 34, 35 MRSA - ESBL 35 DNA 36 C. albicans 2 2 C. albicans CDR 37 Candida spp. 99 AIDS C. albicans 38 3 SENTRY Antimicrobial Resistance Surveillance Program SENTRY Program objective A objective B, C objective Dobjective E
6 Candida spp caspofungin ; CAS SENTRY Program ARTEMIS Global Antifungal Susceptibility Program ARTEMIS Program Candida spp ARTEMIS Program SENTRY Program Candida ,75 3 2, , ,448 CAS C. a C. gl a C. p C. t Pfaller et al Pfaller et al 2 39 b Pfaller et al 2 4 C. a. C. albicans ; C.gl. C. glabrata ; C. p. C. parapsilosis ; C.t. C. tropicalis ; C.k. C. krusei ; C.l. C. lusitaniae aclsi M27-A b c d, MIC e MIC µg ml C. k C. l. 7. b c Pfaller et al 22 4 d Messer et al e Messer et al 29 43
7 7 C. albicans, C. parapsilosis C. tropicalis C. glabrata C. krusei 7.2 C. krusei C. glabrata C. krusei C. glabrata CDR 5 C. glabrata 9 C. krusei, 5 53 C. albicans 5 C. glabrata C. krusei C. albicans, C. parapsilosis C. tropicalis C. glabrata ARTEMIS Program SENTRY Program Candida 2, , , ,959 8,97 2,656 CAS a CAS a MCFG a CAS C. a. b b.5 b.2 b 2 c b C. gl C. a. C. albicans ; C.gl. C. glabrata ; C. p. C. parapsilosis ; C.t. C. tropicalis ; C.k. C. krusei ; C.gu. C. guilliermondii ; C.l. C. lusitaniae a MIC 2µg ml bclsi M27-A Etest cclsi M27-A C. p C. t C. k C. gu C. l Pfaller et al ARTEMIS Program Pfaller et al ARTEMIS Program Pfaller et al ARTEMIS Program Pfaller et al Pfaller et al Pfaller et al 26 49
8 C. krusei 2 4 C. albicans, C. parapsilosis C. tropicalis C. krusei 7.7 C. glabrata 3 longitudinal study ARTEMIS Program 46 JAS Program Candida spp. ARTEMIS Program JAS Program 2 Candida Candida C. albicans ARTEMIS Program JAS Program C. glabrata ARTEMIS Program JAS Program C. parapsilosis ARTEMIS Program JAS Program C. tropicalis ARTEMIS Program JAS Program C. krusei ARTEMIS Program JAS Program C. guilliermondii ARTEMIS Program JAS Program C. lusitaniae ARTEMIS Program JAS Program 6.7 ARTEMIS Program 25,44 JAS Program,486
9 , 57 C. glabrata in vitro 58 6 C. krusei in vitro 57 C. krusei 6 63 C. krusei CYP5 64, 65 C. krusei C. glabrata SENTRY Program 2 C. krusei C. tropicalis C. krusei Candida spp. C. albicans Cr. neoformans 66 C. albicans 5 CLSI Candida spp Cr. neoformans , 7 C. krusei 5 7, 72 Candida spp SENTRY Program 43 C. albicans Candida spp. C. krusei 6.9 Trichosporon spp. C. lusitaniae 73, 75 C. lusitaniae 76 CLSI M27 CLSI M44 Etest 77 C. krusei C. lusitaniae C. glabrata 78 CAS, MCFG anidulafungin 3 3 Candida spp.
10 48, 49, 79, C. albicans, C. glabrata, C. tropicalis, C. krusei, C. lusitaniae C. parapsilosis C. guilliermondii Candida spp. 84, , C. guilliermondii C. parapsilosis Candida spp. C. albicans, C. glabrata, C. krusei 78, 82, 83, in vitro in vivo 9 SENTRY Program 3 38, 4, 42 ARTEMIS Program 48 SENTRY Program ARTEMIS Program 2 4 ARTEMIS Program Taiwan Surveillance of Antimicrobial Resistance of Yeasts TSARY 92, 93 Candida spp , Japan Invasive Mycosis Surveillance JIMS study group Candida spp ,,,,, MCFG
11 Japan Antifungal Surveillance JAS Program ,56 Candida spp.,486 2 JIMS JAS Program C. albicans, C. parapsilosis C. tropicalis.8,.8, 3.2 vs..2, 4.6,.4,.8, 4.8 vs..2,,.5 Candida , ,448 CAS Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis Candida Candida spp Candida spp Pfaller et al ARTEMIS Program Pfaller et al 2 4 ARTEMIS Program Messer et al SENTRY Program Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis Candida spp. C. albicans C. glabrata C. parapsilosis C. tropicalis ,329 C. albicans C. glabrata C. tropicalis Pfaller et al ARTEMIS Program C. albicans C. glabrata C. tropicalis
12 Candida MCFG MCFG MCFG MCFG MCFG C. a. C. gl. C. p. C. t. C. k. C. gu. C. l MCFG MCFG , a Takakura et al Japan Invasive Mycosis Surveillance JIMS 3 C. a. C. albicans ; C.gl. C. glabrata ; C. p. C. parapsilosis ; C.t. C. tropicalis ; C.k. C. krusei ; C.gu. C. guilliermondii ; C.l. C. lusitaniae a MIC CLSI M27-A MCFG 24 b b) Japan Antifungal Surveillance JAS Program
13 5 C. glabrata 5.2 vs vs. 2. C. krusei 53.8 vs. 59 vs ARTEMIS Program C. glabrata ARTEMIS Program 5 Candida spp. C. krusei 5 C. albicans C. tropicalis 98 JIMS JAS Program 3 C. albicans.4 vs..2, C. parapsilosis.8 vs., C. tropicalis 4.8 vs..5 2 C. glabrata 56.3 vs. 4.3 C. krusei 38.5 vs. 6.9 JIMS JAS Program C. glabrata C. krusei, MCFG 3 3 JIMS 8 C. tropicalis MCFG JAS Program 3,, ARTEMIS Program 2 C. glabrata C. krusei 57 93
14 , Aspergillus spp. Candida spp. Scedosporium apiospermum Aspergillus terreus A. terreus A. fumigatus A. flavus Aspergillus spp. A. fumigatus b 6, 7 A. fumigatus Aspergillus A. lentulus 6 Aspergillus in vitro A. fumigatus 3, 8, , 3 3 A. fumigatus in vitro in vivo 4 posaconazole ravuconazole isavuconazole A. fumigatus 26 Candida spp. Aspergillus spp. A. fumigatus 43, 54 56, Aspergillus spp. 45 non-fumigatus Aspergillus spp. A. niger 24, A. versicolor 4 A. fumigatus 553 SENTRY Program 43 A. fumigatus 49 3 A. fumigatus JAS Program A. fumigatus 26 A. fumigatus A. terreus A. fumigatus Aspergillus spp. Candida spp. A. fumigatus
15 Aspergillus spp. A. fumigatus A. fumigatus A. flavus A. niger A. terreus A. versicolor Aspergillus spp SENTRY Program 49 A. fumigatus A. fumigatus 3 2 A. fumigatus A. fumigatus A. fumigatus Pfaller et al 28 5 A. flavus A. niger 24 A. terreus A. versicolor 4 Aspergillus spp Messer et al Verweij et al 22 6 Dannaoui et al JAS Program Candida spp. Aspergillus spp. 2 3 MIC 4 HAART high active antiretroviral therapy
16 HIV C. albicans : , 2 2 Viscoli C, Girmenia C, Marinus A, et al : Candidemia in cancer patients : a prospective, multicenter surveillance study by the Invasive Fungal Infection Group IFIG of the European Organization for Research and Treatment of Cancer EORTC. Clin Infect Dis, : 7-79, Lin SJ, Schranz J, Teusch SM : Aspergillosis case-fatality rate : systemic review of the literature. Clin Infect Dis, : , 2 4 Roden MM, Zaoutis TE, Buchanan WL, et al : Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, : , 25 5 Cosgrove SE, Sakoulas G, Perencevich EN, et al : Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia : a meta-analysis. Clin Infect Dis, : 53-59, 23 6 White TC, Marr KA, Bowden RA, et al : Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev, : , Ghannoum MA, Rice LB : Antifungal agents : mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev, : 5-57, Perea S, Patterson TF : Antifungal resistance in pathogenic fungi. Clin Infect Dis, : 73-8, 22 9 Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis : a persistent public health problem. Clin Microbiol Rev, : 33-63, 27 Kanafani ZA, Perfect JR : Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis, : 2-28, 28 Hof H : Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur J Clin Microbiol Infect Dis, : , 28 2 Marichal P, Koymans L, Willemsens S, et al : Contribution of mutations in the cytochrome P45 4 alphademethylase Erg p, Cyp5p to azole resistance in Candida albicans. Microbiology, : , Denning DW, Venkateswarlu K, Oakley KL, et al : Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother, : , Verweij PE, Mellado E, Melchers WJ : Multiple-triazoleresistant aspergillosis. N Engl J Med, : , 27 5 Nguyen MH, Peacock JE, Morris JA, et al : The changing face of candidemia-emergence of non-candida albicans species and antifungal resistance. Am J Med, : , Marty FM, Cosimi LA, Baden LR : Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplant. N Engl J Med, : , 24 7 Matsue K, Koseki M, Asada N, et al : Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis, : , 26 8 Clinical and Laboratory Standards Institute : Reference method for broth dilution antifungal susceptibility testing of yeasts ; Approved standard-third edition M27-A3. CLSI, Wayne, PA, USA, 28 9 Clinical and Laboratory Standards Institute : Reference method for broth dilution antifungal susceptibility testing of filamentous fungi ; Approved standard-second edition M38-A2. CLSI, Wayne, PA, USA, 28 2 Clinical and Laboratory Standards Institute : Method for antifungal disk diffusion susceptibility testing of yeasts ; Approved guideline-second edition M44-A2. CLSI, Wayne, PA, USA, 29 2 No.2 : 39-32, Clinical and Laboratory Standards Institute : Reference method for broth dilution antifungal susceptibility testing of yeasts ; Third informational supplement M27-S3. CLSI, Wayne PA, USA, Pfaller M, Diekema DJ, Ostrosky-Zeichner L, et al : Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin : analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol, : , Alves SH, Lopes JO, Costa JM, et al : Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS. Rev Int Med Trop Sao Paulo, : , Casadevall A, Spitzer ED, Webb D, et al : Susceptibilities of several Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis, Antimicrob Agents Chemother, : , Howard S, Webster I, Moore BC, et al : Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents, : , Denning DW, Radford SA, Oakley KL, et al : Correlation
17 between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother, : 4-44, Gomez-Lopez A, Aberkane A, Petrikkou E, et al : Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp.. J Clin Microbiol, : , Lass-Flörl C, Perkhofer S, Mayr A : In vitro susceptibility testing in fungi : a global perspective on a variety of methods. Mycoses, : -, 2 3. p.6-37, : , BMSA : 2-, Opal SM, Medeiros AA : Molecular mechanisms of antibiotic resistance in bacteria. In : Mandell GL, Bennett JE, Dolin eds Mandell, Douglas, and Bennett s Principle and Practice of Infectious Diseases, p , Churchill Livingstone, Philadelphia, Hawkey PM, Jones AM : The changing epidemiology of resistance. J Antimicrob Chemother, : i3- i, Anderson JB : Evolution of antifungal-drug resistance : mechanisms and pathogen fitness. Nat Rev Microbiol, : , Cowen LE : Predicting the emergence of resistance to antifungal drugs. FEMS Microbiol Lett, : -7, 2 37 Coste A, Turner V, Ischer F, et al : A mutation in Tacp, a transcription factor regulating CDR and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics, : , Pfaller MA, Jones RN, Doern GV, et al : International surveillance of blood stream infections due to Candida species : frequency of occurrence and antifungal susceptibilities of isolates collected in 997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol, : , Pfaller MA, Jones RN, Doern GV, et al : Blood stream infections due to Candida species : SENTRY Antimicrobial Surveillance Program in North America and Latin America, Antimicrob Agents Chemother, : , 2 4 Pfaller MA, Diekema DJ, Jones RN, et al : International surveillance of blood stream infections due to Candida species : frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 997 through 999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol, : , 2 4 Pfaller MA, Diekema DJ, Jones RN, et al : Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with blood stream infections : SENTRY Antimicrobial Surveillance Program, 997 to 2. J Clin Microbiol, : , Messer SA, Jones RN, Fritsche TR, et al : International surveillance of Candida spp. and Aspergillus spp.: reports from the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol, : , Messer SA, Moet GT, Kirby JT, et al : Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program 26 to 27. J Clin Microbiol, : , Pfaller MA, Diekema DJ, Messer SA, et al : Activities of fluconazole and voriconazole against,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods : report from the ARTEMIS Global Antifungal Susceptibility Program, 2. J Clin Microbiol, : , Pfaller MA, Messer SA, Boyken L, et al : In vitro activities of voriconazole, posaconazole, and fluconazole against 4,69 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2 and 22 in the ARTEMIS Global Antifungal Surveillance Program. Diag Microbiol Infect Dis, : 2-25, Pfaller MA, Diekema DJ, Gibbs DL, et al : Results from the ARTEMIS DISK Global Antifungal Surveillance Study, : an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol, : , Pfaller MA, Diekema DJ, Messer SA, et al : In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 57 fluconazole-resistant isolates. Antimicrob Agents Chemother, : 68-7, Pfaller MA, Boyken L, Hollis RJ, et al : In vitro susceptibilities of Candida spp. to caspofungin : four years of global surveillance. J Clin Microbiol, : , Pfaller MA, Boyken L, Hollis RJ, et al : Global surveillance of in vitro activity of micafungin against Candida : a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol, : , 26 5 Bennett JE, Izumikawa K, Marr KA : Mechanisms of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother, : , 24 5 Marr KA, White TC, van Burik JA, et al : Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis, : 98-9, Marr KA, Lyons CN, Rustad TR, et al : Rapid, transient fluconazole resistance in Candida albicans is associated with increased mrna levels of CDR. Antimicrob Agents Chemother, : , Martins MD, Lozano-Chiu M, Rex JH : Declining rates of
18 oropharyngeal candidiasis and carriage of Candida albicans associated with trends towards reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis, : , Japan Antifungal Surveillance Program : 83-93, Japan Antifungal Surveillance Program : 3-22, Japan Antifungal Surveillance Program : 28-4, Pfaller MA, Diekema DJ, Sheehan DJ : Interpretive breakpoints for fluconazole and Candida revisited : a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev, : , Ables AZ, Blumer NA, Valainis GT, et al : Fluconazole prophylaxis of severe Candida infections in trauma and postsurgical patients : a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract, : 69-75, 2 59 Magill SS, Shields C, Sears CL, et al : Triazole crossresistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol, : , 26 6 Panackal AA, Gribskov JL, Staab JF, et al : Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol, : , 26 6 Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, et al : Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis, : , Kullberg BJ, Sobel JD, Rhunke M, et al : Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients : a randomized non-inferiority trial. Lancet, : , Pfaller MA, Diekema DJ, Rex JH, et al : Correlation of MIC with outcome for Candida species tested against voriconazole : analysis and proposal for interpretive breakpoints. J Clin Microbiol, : , Fukuoka T, Johnston DA, Winslow CA, et al : Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother, : 23-29, Spellberg BJ, Filler SG, Edwards, JE Jr : Current treatment strategies for disseminated candidiasis. Clin Infect Dis, : , Schonebeck J, Anséhn S : 5-Fluorocytosine resistance in Candida spp. and Torulopsis glabrata. Sabouraudia, : -2, Price MF, LaRocco MT, Gentry LO : Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother, : , Brandt ME, Pfaller MA, Hajjeh RA, et al : Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States : 992 to 994 and 996 to 998. Antimicrob Agents Chemother, : , 2 69 Francis P, Walsh TJ : Evolving role of flucytosine in immunocompromised patients : new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis, : 3-8, Vanden Bossche H, Warnock DW, Dupont B, et al : Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol, : 89-22, Bennett JE, Dismukes WE, Duma RA, et al : A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med, : 26-3, Hospenthal DR, Bennett JE : Flucytosine monotherapy for cryptococcosis. Clin Infect Dis, : , Powderly WG, Kobayashi GS, Herzig GP, et al : Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med, : , Walsh TJ, Melcher GP, Rinaldi MG, et al : Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol, : , Pfaller MA, Messer SA, Hollis RJ : Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis, : 27-33, Rex JH, Cooper CR Jr, Merz WG, et al : Detection of amphotericin B-resistant Candida isolates in a brothbased system. Antimicrob Agents Chemother, : 96-99, Wanger A, Mills K, Nelson PW, et al : Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing : enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother, : , Krogh-Madsen M, Arendrup MC, Heslet L, et al : Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis, : , Ostrosky-Zeichner L, Rex JH, Pappas PG, et al : Antifungal susceptibility survey of 2, bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, : , 23 8 Pfaller MA, Boyken L, Hollis RJ, et al : In vitro activities of anidulafungin against more than 2,5 clinical isolates of Candida spp., including 35 isolates resistant to fluconazole. J Clin Microbiol, : , 25 8 Moudgal V, Little T, Boikov D : Multiechinocandin-and multi-azole resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
19 Antimicrob Agents Chemother, : , Hakki M, Staab JF, Marr KA : Emergence of Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother, : , Laverdiere M, Lalonde RG, Baril JG, et al : Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother, : 75-78, Green LJ, Marder P, Mann LL, et al : LY exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrob Agents Chemother, : , Tawara S, Ikeda F, Maki K, et al : In vitro activities of a new lipopeptide antifungal agents, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother, : 57-62, 2 86 Barchiesi F, Spreghini E, Tomassetti S, et al : Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother, : , Hemandez S, Lopez-Ribot JL, Najivar LK, et al : Caspofungin resistance in Candida albicans : correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother, : , Park S, Kelly R, Kahn JN, et al : Specific substitutions in the echinocandin target FKsp accounts for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother, : , Miller CD, Lomaestro BW, Park S, et al : Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy, : , 26 9 Katiyar S, Pfaller M, Edlind T : Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother, : , 26 9 Rogers TR, Johnson EM, Munro C : Echinocandin drug resistance. J Invasive Fungal Infect, : 99-5, Yang YL, Li SY, Chang HH, et al : Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY. Diagn Microbiol Infect Dis, : 79-83, Yang YL, Cheng MF, Wang CW, et al : The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from steril sites in Taiwan. Med Mycol, : , 2 94 in vitro fluconazole in vitro in vivo. : 5-22, Candida albicans. : 83-89, : 28-35, : , micafungin FK463 in vitro Candida. : Takakura S, Fujihara N, Saito T, et al : National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother, : , 24. Jpn J Antibiotics, : 75-7, 23. : 74-8, 26 2 Candida in vitro. : 2-24, 25 3 Candida. : , 27 4 Pfaller MA, Diekema DJ : Rare and emerging opportunistic fungal pathogens : concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol, : , 24 5 Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, et al : In vitro activities of various antifungal drugs against Aspergillus terreus : global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother, : , 29 6 Balajee S, Gribskov J, Hanley E, et al : Aspergillus lentulus sp. nov., a new sibling Species of A. fumigatus. Eukaryot Cell, : , 25 7 Balajee S, Nickle D, Varga J, et al : Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell, : 75-72, 26 8 Chryssanthou E : In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis, : 59-52, Dannaoui E, Persat F, Monier MF, et al : In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother, : , 997 Moore CB, Sayers N, Mosquera J, et al : Antifungal drug resistance in Aspergillus. J Infect, : 23-22, 2
20 Gomez-Lopez A, Garcia-Effron G, Mellado E, et al : In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother, : , 23 2 Mosquera J, Denning DW : Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother, : , 22 3 Pfaller MA, Diekema DJ, Ghannoum MA, et al : Wild-type MIC MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol, : , 29 4 Van den Linden JWM, Jansen RR, Bresters D, at al : Azole-resistant central nervous system aspergillosis. Clin Infect Dis, : -3, 29 5 Pfaller MA, Messer SA, Boyken L, et al : In vitro survey of triazole cross-resistance among more than 7 clinical isolates of Aspergillus species. J Clin Microbiol, : , 28 6 Verweij PE, TeDorsthorst DTA, Rijs AJMM, et al : Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 945 and 998. J Clin Microbiol, : , 22 7 Dannaoui E, Meletiadis J, Tortorano A-M, et al : Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. J Med Microbiol, : 29-34, 24 8 Zingman BS : Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med, : , Valdez H, Gripshoven BM, Salata RA, et al : Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS, : 538, Martins MD, Lozano-Chin M, Rex JH : Declining rates of oropharyngeal candidiasis and carriage of Candida albicans with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis, : , Maragakis LL, Perencevich EN, Cosgrove SE : Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther, : , 28
1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationKey words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
5. Page1 5. (1) 500 /mm 3 500 /mm 3 1,2,3) CDC Centers for Disease Control and Prevention, Atlanta ational osocomial Infections Surveillance Candida spp. 4 7.3 16.1% 4,5) 1980 1989 AIDS 1997 100,000 0.3
More informationKey words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant
Key words: Candida, fungemia, antifungal activity, micafungin, fluconazole-resistant Fig. 1 Annual changes in percentages of fungi isolated from blood and vascular catheters Fig. 2 Frequencies of fungi
More informationVOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
More informationCandida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
More informationCHEMOTHERAPY FEB. 1994
CHEMOTHERAPY FEB. 1994 CHEMOTHERAPY FEB. 1994 Table 1. In vitro effect of flucytosine combined with fluconazole on Candida app. Fig. 1. Chemotherapeutic effect of combinations of flucytosine and uconazole
More information164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationb) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
More informationFig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More information38 38 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 Feb CT A B A CT B 20xx 2 8 LAM 20xx 1 12 CT S6, S10 Aspergillus spp. Micafungin MCFG 150 mg/ I
Feb. 2013 THE JAPANESE JOURNAL OF ANTIBIOTICS 66 1 37 37 Liposomal amphotericin B 1 2 2 2 1 1 1 2 1 1 2 2012 12 25 33 Lymphangioleiomyomatosis: LAM 2 20xx 1 CT Aspergillus spp. Micafungin MCFG Itraconazole
More information日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More informationKey words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More information日本化学療法学会雑誌第50巻新薬特集号
micafungin in vitro 3 3 micafungin Candida Aspergillus Candida albicans fluconazole Candida tropicalis, Candida glabrata, Candida krusei Aspergillus 90 MIC90 0. g ml amphotericin B fluconazole itraconazole
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More informationCHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More information13●53頁●6-7▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
More information-95-
-95- -96- 日中医学協会助成事業 中国吉林省にて分離された Candida guilliermondii の薬剤感受性試験と播種性マウ スモデルにおける micafungin の有用性 研究者氏名 Dongmei Jia 中国所属機関北華大学附属病院 吉林市 吉林省 中国日本研究期間長崎大学大学院医歯薬学総合研究科感染免疫学講座指導責任者教授河野茂共同研究者泉川公一 宮崎泰可 要旨中国吉林省の医療施設で分離されたカンジダ属
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More information/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
More informationCHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More information感染症学雑誌第80巻第6号
Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More informationCHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More information1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
More informationVOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
More informationCHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
More information2) Goetz, A., Tsuneishi, N.: Application of molecular filter membranes to the bacteriological analysis of water, J. Am. Water Works Assn., 43 (12): 943-969,1951. 3) Clark, H.F. et al.: The membrane filter
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationA A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationTable1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More information1) Garner J. S.: The Hospital Infection Control Practices Advisory Committee, CDC, Guidelines for Isolation Precautions in Hospitals, 1996. http://wonder.cdc.gov/wonder/prevguid/ p0000419/p0000419.asp.
More informationUnderstanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
More informationTable 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationVOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
More informationVOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
More informationTable 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae
Key words: penicillin insensitive and resistant pneumococcus Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae 小 児
More informationOct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
More information15) Egawa, R., Sawai, T. and Mit.uhashi, S.: Jap. J. Microbiol., 11 : 173-178, 1967. 16) Tanaka, T. and Hashimoto, H., Nagai, Y. and Mitsuhashi, S.: Jap. J. Microbiol., 11: 155-162, 1967. 17) Mitsuhashi,
More informationMicrosoft Word - 「黄砂とその健康影響について」小冊子180323版
...1...1...1...2...4...4...4...6...7...7...7...7...8...8...9...9...10... 11... 11... 11... 11...12...12...13...16...18...20 1 1-1 1-2 1 1 km 24.5 m/s 10 50 m 1 1-3 μm 1-4 1-5 2 8 http://www.jma-net.go.jp/sat/himawari/obsimg/image_dust.html
More informationSome Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni
Title 尿路 Candida 症に於ける 2,3 の検索 Author(s) 山本, 忠治郎 ; 水谷, 三 ; 佐藤, 徳郎 Citation 泌尿器科紀要 (1961), 7(3): 394-405 Issue Date 1961-03 URL http://hdl.handle.net/2433/112109 Right Type Departmental Bulletin Paper Textversion
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More information_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
More informationCHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More informationC/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
More informationICT 1 21 ICT., Cooper, Dawson
- - - morin@adm.ncn.ac.jp Readiness and educational program for infection control link nurse Namiko Mori-YoshikawaMidori Nishioka National College of Nursing, Japan ; - - Umezono, Kiyose-shi, Tokyo, -,
More informationVOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
More information) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
More informationTable 1 Eight clinical cases with candidemia gra.; granulocytopenia (<400/ml) before candidemia AMoL; acute monocytic leukemia VH; intravenous yperali
Key words: candidemia, HA-test, Cand-Tec, D-arabinitol, Ĉ-d-glucan Table 1 Eight clinical cases with candidemia gra.; granulocytopenia (
More informationKey Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar
More information2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11
1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
More informationVOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
More information名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
More information1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
More information14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
More informationKey words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
More informationKey words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin Table 1 Differentiation of group D streptococcia aderived from R.R.Facklam1,2),K.C.Gross-et al3),and
More informationTable 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio
Key words: Legionella pneumonia, culture-positive, Japanese patients Legionella (L. pneumophila (L. micdadei, L. bozemanii, Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990
More informationVOL. 36 S-3 CHEMOTHERAPY 437
VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,
More informationTable 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
More information